Cocrystal Pharma, Inc.

COCP • Biotechnology

$0.94

▼ -0.00 (-0.39%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$13.00M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.24Healthy liquidity · 3.68Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.94

Change-0.39%

Shares Out13.79M

Market Cap$13.00M

Enterprise Value$12.17M

52W Range0.76 - 2.67

Beta1.43

P/E-1.31

P/S57.78

P/B12.45

P/FCF-1.59

EV/Sales54.10

Price$0.94

Change-0.39%

Shares Out13.79M

Market Cap$13.00M

Enterprise Value$12.17M

52W Range0.76 - 2.67

Beta1.43

P/E-1.31

P/S57.78

P/B12.45

P/FCF-1.59

EV/Sales54.10

EV/EBITDA-1.26

EV/FCF-1.49

Earnings Yield-76.44%

FCF Yield-62.71%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.24

Current Ratio3.68

Quick Ratio3.68

Volume35.92K

Avg Volume85.21K

EPS Surprise-0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

89/100

Why this score▼

Manageable debt level · 0.24Healthy liquidity · 3.68Weak profitability

Analyst view

Analyst sentiment and price target

COCP

Analyst sentiment

Based on 1 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 2/22/2012

Industry: Biotechnology

P/B i: 12.45

Debt / Equity i: 0.24

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.24

Current Ratio: 3.68

Quick Ratio: 3.68

Status: Good

Insider Transactions

Recent executive and insider activity

FROST PHILLIP MD ET AL

Transaction: 08/05/2026

BUY

Change

+10,000

Price

$0.98

Filing

08/06/2026

Type

BUY

FROST PHILLIP MD ET AL

Transaction: 08/03/2026

BUY

Change

+75,000

Price

$0.94

Filing

08/05/2026

Type

BUY

SAPIRSTEIN JAMES

Transaction: 06/03/2026

OTHER

Change

Price

Not reported

Filing

06/03/2026

Type

OTHER

Insider	Type	Change	Price	Transaction	Filing
FROST PHILLIP MD ET AL	BUY	+10,000	$0.98	08/05/2026	08/06/2026
FROST PHILLIP MD ET AL	BUY	+75,000	$0.94	08/03/2026	08/05/2026
SAPIRSTEIN JAMES	OTHER	0	Not reported	06/03/2026	06/03/2026
FROST PHILLIP MD ET AL	BUY	+20,000	$1.00	02/24/2026	02/25/2026
FROST PHILLIP MD ET AL	BUY	+50,000	$0.95	02/06/2026	02/09/2026
Rubin Steven D	BUY	+16,410	$1.10	01/09/2026	01/13/2026
Japour Anthony J	BUY	+16,410	$1.10	01/09/2026	01/13/2026
FROST PHILLIP MD ET AL	BUY	+24,615	$1.10	01/09/2026	01/13/2026
Martin James Joseph	BUY	+49,229	$1.10	01/09/2026	01/13/2026
Hassan Fred	BUY	+16,410	$1.10	01/09/2026	01/13/2026
Lee Sam	BUY	+49,229	$1.10	01/09/2026	01/13/2026
PFENNIGER RICHARD C JR	BUY	+16,410	$1.10	01/09/2026	01/13/2026
Kornberg Roger D.	BUY	+24,615	$1.10	01/09/2026	01/13/2026
FROST PHILLIP MD ET AL	BUY	+50,000	$0.95	12/31/2025	01/02/2026
FROST PHILLIP MD ET AL	BUY	+20,000	$0.97	12/30/2025	12/31/2025
FROST PHILLIP MD ET AL	BUY	+40,000	$0.97	12/26/2025	12/29/2025
FROST PHILLIP MD ET AL	BUY	+25,000	$0.97	12/24/2025	12/29/2025
FROST PHILLIP MD ET AL	BUY	+1,500	$1.00	11/26/2025	11/28/2025
FROST PHILLIP MD ET AL	BUY	+20,000	$0.94	11/25/2025	11/25/2025
Martin James Joseph	BUY	+7,196	$1.24	10/28/2025	10/30/2025

About the Company

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Source - link

Peers

BOLT BRTX CING DWTX EVGN IMNN IMRN MRKR SNSE TRAW

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.

GlobeNewsWire

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

GlobeNewsWire

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year.

GlobeNewsWire

Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Institutional and Insider Ownership 35.0% of Zevra

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-21	-0.15	-0.16	-0.01
2026-05-15	-0.15	-0.17	-0.02
2025-11-14	-0.22	-0.19	0.03
2025-08-14	-0.3	-0.2	0.1
2025-05-15	-0.52	-0.23	0.29
2025-03-31	-0.55	-0.32	0.23
2024-11-13	-0.57	-0.49	0.08
2024-08-14	-0.51	-0.53	-0.02
2024-05-13	-0.54	-0.39	0.15
2024-03-28	-0.57	-0.44	0.13
2023-11-13	-0.47	-0.41	0.06
2023-08-14	-0.53	-0.5	0.03